This POV describes Colorado House Bill 19-1131 and how it could affect pharma marketers. The bill requires that any one-to-one communications between pharmaceutical representatives (or anyone communicating on their behalf) and prescribers must include written information about the wholesale cost of a drug, as well as the names of at least three generic equivalents. The law goes into effect on August 2, 2019.
Harmonious collaboration produces the best work from your agencies, but getting everyone to be on the same page can be a challenge. How do you ensure that everyone’s doing their part? How can you work effectively and efficiently when there are multiple players, multiple meetings and – more than likely
On July 8, U.S. District Court Judge Amit Mehta ruled that the Department of Health and Human Services had overstepped its authority in requiring pricing disclosures. What happens next?
On Monday, June 24, 2019, the Food and Drug Administration finalized its guidance on electronic submissions of promotional materials. This Intouch POV provides an overview of the most significant aspects of the guidance, including the most important changes from the 2015 draft version.
Mary Meeker, tech maven and founder of the newly formed Bond Capital -- and former partner at venture-capital firm Kleiner Perkins Caufield & Byers -- recently presented her latest internet trends report at Recode’s Code 2019 conference, and this one was nearly as large as the 2017 presentation. This recap highlights what’s relevant for pharma marketers.
Kick back with the television, a magazine, or some quality YouTube time, and you’re likely to see diversity and inclusion in many ads. Ideally, you’ll see differently abled people, interracial couples with biracial children, active seniors, same-sex couples, people of short stature, full-figured models, and friend groups that resemble the
At the Coalition’s Rising Leaders conference on healthcare policy in Washington, D.C. May 22, a diverse set of speakers provided updates and predictions, and discussed the potential impact of the many significant healthcare policy decisions pending on Capitol Hill. This POV provides an overview of five issues to watch that were highlighted at the conference, as well as strategies for addressing them.
In the wake of the May 8 list-price mandate for DTC TV ads issued by the Centers for Medicare & Medicaid Services (CMS) -- and, even before that, since the draft rule was issued in October 2018 -- one of the questions we are hearing from clients is, “What about YouTube?” Read on to learn more.
On May 8, 2019, the Trump administration announced that the Centers for Medicare & Medicaid Services (CMS) would require drugs covered by Medicare or Medicaid to include a list price in any DTC television commercial within 60 days of the announcement, if their list price is at least $35 for a month’s supply or a course of treatment. The ruling is virtually the same as the one proposed in October 2018, and only products that advertise on TV are affected directly by the ruling. This POV provides a brief summary of the background to this ruling, a summary of its specifics, some reactions to it, and our recommendations to clients in its wake.